EP1381598A4 - Nouveaux inhibiteurs de la tyrosine kinase - Google Patents
Nouveaux inhibiteurs de la tyrosine kinaseInfo
- Publication number
- EP1381598A4 EP1381598A4 EP02723631A EP02723631A EP1381598A4 EP 1381598 A4 EP1381598 A4 EP 1381598A4 EP 02723631 A EP02723631 A EP 02723631A EP 02723631 A EP02723631 A EP 02723631A EP 1381598 A4 EP1381598 A4 EP 1381598A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- novel tyrosine
- novel
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27932701P | 2001-03-28 | 2001-03-28 | |
US279327P | 2001-03-28 | ||
PCT/US2002/009402 WO2002079192A1 (fr) | 2001-03-28 | 2002-03-26 | Nouveaux inhibiteurs de la tyrosine kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1381598A1 EP1381598A1 (fr) | 2004-01-21 |
EP1381598A4 true EP1381598A4 (fr) | 2008-03-19 |
Family
ID=23068491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02723631A Withdrawn EP1381598A4 (fr) | 2001-03-28 | 2002-03-26 | Nouveaux inhibiteurs de la tyrosine kinase |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1381598A4 (fr) |
JP (1) | JP2004534010A (fr) |
KR (1) | KR20030083016A (fr) |
CN (1) | CN1514833A (fr) |
AR (1) | AR035804A1 (fr) |
BG (1) | BG108206A (fr) |
BR (1) | BR0208373A (fr) |
CA (1) | CA2442428A1 (fr) |
CZ (1) | CZ20032615A3 (fr) |
EE (1) | EE200300475A (fr) |
GE (1) | GEP20053660B (fr) |
HR (1) | HRP20030844A2 (fr) |
HU (1) | HUP0400323A2 (fr) |
IL (1) | IL158041A0 (fr) |
IS (1) | IS6968A (fr) |
MX (1) | MXPA03008690A (fr) |
NO (1) | NO20034308L (fr) |
PE (1) | PE20021015A1 (fr) |
PL (1) | PL373300A1 (fr) |
RU (1) | RU2003131693A (fr) |
SK (1) | SK12002003A3 (fr) |
UY (1) | UY27234A1 (fr) |
WO (1) | WO2002079192A1 (fr) |
YU (1) | YU84603A (fr) |
ZA (1) | ZA200307466B (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
US7265260B2 (en) | 2002-03-01 | 2007-09-04 | Bristol-Myers Squibb Company | Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors |
EP1534703A2 (fr) * | 2002-06-12 | 2005-06-01 | Abbott Laboratories | Antagonistes du recepteur de l'hormone de melano-concentration |
US7361691B2 (en) * | 2002-12-02 | 2008-04-22 | Arqule, Inc. | Method of treating cancers using β-lapachone or analogs or derivatives thereof |
US7189716B2 (en) | 2003-01-03 | 2007-03-13 | Bristol-Myers Squibb Company | Tyrosine kinase inhibitors |
EP1590339A4 (fr) * | 2003-01-28 | 2007-07-25 | Smithkline Beecham Corp | Composes chimiques |
US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
JP5010917B2 (ja) * | 2003-08-29 | 2012-08-29 | エグゼリクシス, インコーポレイテッド | c−Kit調節因子および使用方法 |
US20050075358A1 (en) * | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
DE102004010207A1 (de) | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
MXPA06011423A (es) | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
KR20070095952A (ko) * | 2004-12-16 | 2007-10-01 | 버텍스 파마슈티칼스 인코포레이티드 | 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Tec 계열 단백질 키나제의 억제제로서 유용한피리드-2-온 |
US7393667B2 (en) | 2005-05-31 | 2008-07-01 | Bristol-Myers Squibb Company | Stereoselective reduction process for the preparation of pyrrolotriazine compounds |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
CN103145738A (zh) | 2005-08-04 | 2013-06-12 | 西特里斯药业公司 | 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物 |
JP2009506123A (ja) * | 2005-08-29 | 2009-02-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン |
EP1919905B1 (fr) | 2005-08-29 | 2011-02-23 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones disubstituées en 3, 5, inhibitrices de la famille tec des tyrosine kinases non liées aux recepteurs |
JP2009507792A (ja) * | 2005-08-29 | 2009-02-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン |
WO2007026720A1 (fr) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | Derive de pyrazole a noyau condense |
US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
WO2007145203A1 (fr) * | 2006-06-13 | 2007-12-21 | Daiichi Fine Chemical Co., Ltd. | 2-amino-1-(4-fluorophenyl) éthanol optiquement actif |
US8063225B2 (en) * | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
WO2008022747A1 (fr) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Dérivés tricycliques de lactame, leur fabrication et leur emploi en tant qu'agents pharmaceutiques |
WO2008025526A1 (fr) * | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Dérivés d'indole, fabrication de ceux-ci et utilisation comme agents pharmaceutiques |
WO2008144345A2 (fr) | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarqueurs et procédés pour déterminer la sensibilité de modulateurs de récepteur de facteur de croissance de type 1 semblable à l'insuline |
TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
CN101687840A (zh) | 2007-06-25 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | 作为激酶抑制剂的苯并咪唑酰胺基衍生物 |
EP2065380A1 (fr) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Dérivés de pyridoneamide comme inhibiteurs de focal adhesion kinase (FAK) et leur utilisation pour le traitement du cancer |
US7816540B2 (en) * | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
EA021464B1 (ru) | 2008-01-22 | 2015-06-30 | Вернэлис (Р&Д) Лтд. | Производные индол-пиридона, обладающие ингибиторной активностью в отношении киназы 1, содержащая их фармацевтическая композиция и их применение |
EP2283020B8 (fr) | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Imidazopyrazines et imidazotriazines substituées |
MX2011006555A (es) | 2008-12-19 | 2011-08-03 | Sirtris Pharmaceuticals Inc | Compuestos de tiazolopiridina moduladores de sirtuina. |
DE102010001064A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
US8513415B2 (en) | 2009-04-20 | 2013-08-20 | OSI Pharmaceuticals, LLC | Preparation of C-pyrazine-methylamines |
CA2763624A1 (fr) * | 2009-05-27 | 2010-12-02 | Abbott Laboratories | Inhibiteurs pyrimidines de l'activite kinase |
WO2011053779A2 (fr) | 2009-10-30 | 2011-05-05 | Bristol-Myers Squibb Company | Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r |
EP3170813B1 (fr) * | 2010-10-06 | 2018-12-12 | GlaxoSmithKline LLC | Dérivés de benzimidazole comme inhibiteurs de pi3 kinase |
WO2012061169A1 (fr) * | 2010-11-01 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Inhibiteurs benzimidazole de production de leucotriènes |
EP2766497A1 (fr) | 2011-10-13 | 2014-08-20 | Bristol-Myers Squibb Company | Procédés de sélection et de traitement du cancer chez des patients au moyen d'inhibiteurs de l'igf-1r/ir |
WO2015004533A2 (fr) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Nouveaux composés bicycliques substitués utilisés comme inhibiteurs de bromodomaines |
CA2915838C (fr) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Inhibiteurs de bromodomaine bicycliques |
WO2015015318A2 (fr) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Nouvelles quinazolones en tant qu'inhibiteurs de bromodomaine |
CN103936719A (zh) * | 2014-05-14 | 2014-07-23 | 中国药科大学 | 苯并咪唑类衍生物制备方法及用途 |
EP3194572B1 (fr) | 2014-07-30 | 2023-10-25 | Yeda Research and Development Co. Ltd. | Milieux pour la culture de cellules souches pluripotentes |
CA2966298A1 (fr) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Pyridinones substituees utilisees comme inhibiteurs de bromodomaines |
CA2966449A1 (fr) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Heterocycles substitues a titre d'inhibiteurs de bromodomaines |
JP2017538721A (ja) | 2014-12-17 | 2017-12-28 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメインの阻害剤 |
JP6827954B2 (ja) * | 2015-04-16 | 2021-02-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 3−(1h−ベンズイミダゾール−2−イル)−1h−ピリジン−2−オン誘導体 |
WO2020152686A1 (fr) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Milieux de culture pour cellules souches pluripotentes |
CN117069696B (zh) * | 2023-08-17 | 2024-04-26 | 中国药科大学 | 一种双靶点小分子抑制剂及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2001000610A1 (fr) * | 1999-06-23 | 2001-01-04 | Aventis Pharma Deutschland Gmbh | Benzimidazoles substitues |
WO2004031401A2 (fr) * | 2002-10-02 | 2004-04-15 | Bristol-Myers Squibb Company | Nouveaux inhibiteurs de tyrosine kinases |
-
2002
- 2002-03-26 YU YU84603A patent/YU84603A/sh unknown
- 2002-03-26 MX MXPA03008690A patent/MXPA03008690A/es unknown
- 2002-03-26 SK SK12002003A patent/SK12002003A3/sk not_active Application Discontinuation
- 2002-03-26 RU RU2003131693/04A patent/RU2003131693A/ru not_active Application Discontinuation
- 2002-03-26 JP JP2002577817A patent/JP2004534010A/ja not_active Withdrawn
- 2002-03-26 CA CA002442428A patent/CA2442428A1/fr not_active Abandoned
- 2002-03-26 PL PL02373300A patent/PL373300A1/xx not_active Application Discontinuation
- 2002-03-26 WO PCT/US2002/009402 patent/WO2002079192A1/fr active Application Filing
- 2002-03-26 IL IL15804102A patent/IL158041A0/xx unknown
- 2002-03-26 EE EEP200300475A patent/EE200300475A/xx unknown
- 2002-03-26 BR BR0208373-6A patent/BR0208373A/pt not_active IP Right Cessation
- 2002-03-26 EP EP02723631A patent/EP1381598A4/fr not_active Withdrawn
- 2002-03-26 CN CNA028105168A patent/CN1514833A/zh active Pending
- 2002-03-26 HU HU0400323A patent/HUP0400323A2/hu unknown
- 2002-03-26 KR KR10-2003-7012594A patent/KR20030083016A/ko not_active Application Discontinuation
- 2002-03-26 GE GE5363A patent/GEP20053660B/en unknown
- 2002-03-26 CZ CZ20032615A patent/CZ20032615A3/cs unknown
- 2002-03-27 UY UY27234A patent/UY27234A1/es not_active Application Discontinuation
- 2002-03-27 PE PE2002000244A patent/PE20021015A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101167A patent/AR035804A1/es not_active Application Discontinuation
-
2003
- 2003-09-25 ZA ZA200307466A patent/ZA200307466B/en unknown
- 2003-09-26 IS IS6968A patent/IS6968A/is unknown
- 2003-09-26 NO NO20034308A patent/NO20034308L/no not_active Application Discontinuation
- 2003-09-26 BG BG108206A patent/BG108206A/bg unknown
- 2003-10-17 HR HR20030844A patent/HRP20030844A2/hr not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2001000610A1 (fr) * | 1999-06-23 | 2001-01-04 | Aventis Pharma Deutschland Gmbh | Benzimidazoles substitues |
WO2004031401A2 (fr) * | 2002-10-02 | 2004-04-15 | Bristol-Myers Squibb Company | Nouveaux inhibiteurs de tyrosine kinases |
Non-Patent Citations (2)
Title |
---|
KATZ B A ET AL: "A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 307, no. 5, 13 April 2001 (2001-04-13), pages 1451 - 1486, XP004466071, ISSN: 0022-2836 * |
See also references of WO02079192A1 * |
Also Published As
Publication number | Publication date |
---|---|
BR0208373A (pt) | 2005-02-22 |
MXPA03008690A (es) | 2003-12-12 |
PE20021015A1 (es) | 2002-11-10 |
NO20034308L (no) | 2003-11-26 |
SK12002003A3 (en) | 2004-10-05 |
IL158041A0 (en) | 2004-03-28 |
PL373300A1 (en) | 2005-08-22 |
NO20034308D0 (no) | 2003-09-26 |
JP2004534010A (ja) | 2004-11-11 |
CA2442428A1 (fr) | 2002-10-10 |
UY27234A1 (es) | 2002-10-31 |
GEP20053660B (en) | 2005-11-10 |
KR20030083016A (ko) | 2003-10-23 |
YU84603A (sh) | 2006-03-03 |
CZ20032615A3 (en) | 2004-03-17 |
ZA200307466B (en) | 2005-01-13 |
CN1514833A (zh) | 2004-07-21 |
HRP20030844A2 (en) | 2005-08-31 |
HUP0400323A2 (hu) | 2005-11-28 |
WO2002079192A1 (fr) | 2002-10-10 |
EP1381598A1 (fr) | 2004-01-21 |
IS6968A (is) | 2003-09-26 |
BG108206A (bg) | 2004-11-30 |
EE200300475A (et) | 2004-02-16 |
AR035804A1 (es) | 2004-07-14 |
RU2003131693A (ru) | 2005-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1381598A4 (fr) | Nouveaux inhibiteurs de la tyrosine kinase | |
AU2003299651A8 (en) | Tyrosine kinase inhibitors | |
EG24381A (en) | Tyrosine kinase inhibitors | |
AU2002361577A1 (en) | Tyrosine kinase inhibitors | |
AU2003282891A8 (en) | Novel tyrosine kinases inhibitors | |
EP1161433A4 (fr) | Inhibiteurs de tyrosine kinase | |
AU2002334355A1 (en) | Protein tyrosine kinase inhibitors | |
AU2003298942A8 (en) | Tyrosine kinase inhibitors | |
HK1049154A1 (zh) | 作為酪氨酸激酶抑制劑的2-吡唑啉-5-酮 | |
AU3704101A (en) | Kinase inhibitors | |
EP1534268A4 (fr) | Inhibiteurs de la tyrosine kinase | |
EP1581539A4 (fr) | Nouveaux inhibiteurs de tyrosine kinase | |
AU2003275282A8 (en) | Novel tyrosine kinase inhibitors | |
AU2002348394A1 (en) | Tyrosine kinase inhibitors | |
EP1259236A4 (fr) | Inhibiteurs de tyrosine-kinase | |
AU2002348020A1 (en) | Tyrosine kinase inhibitors | |
AU2002348393A1 (en) | Tyrosine kinase inhibitors | |
EP1651599A4 (fr) | Inhibiteurs des tyrosine kinases | |
EP1496897A4 (fr) | Inhibiteurs de tyrosines kinases | |
AU2002323406A1 (en) | Tyrosine kinase inhibitors | |
AU2002327534A1 (en) | Tyrosine kinase inhibitors | |
AU2002253350A1 (en) | 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors | |
EP1651209A4 (fr) | Inhibiteurs de tyrosine kinase | |
GB0201384D0 (en) | Tyrosine kinase inhibitors | |
AU2002322568A1 (en) | Tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031028 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1060577 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080218 |
|
17Q | First examination report despatched |
Effective date: 20091124 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1060577 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120724 |